New Alzheimer's drug candidate passes first safety hurdle in small trial

NCT ID NCT05804383

Completed Disease control Sponsor: Allyx Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested the safety of a new drug called BMS-984923 in 51 healthy older adults and people with Alzheimer's disease. Participants received either the drug or a placebo to check for side effects and how the body processes the medication. The goal was to see if the drug is safe enough for further testing, not to measure if it helps symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-984923
What this could lead to: If successful, this could pave the way for a new treatment to control Alzheimer's disease progression.
What could go wrong: This is a very early Phase 1 trial focused only on safety and dosing, not on effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Spaulding Clinical Research

West Bend, Wisconsin, 53095, United States
Yale University

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.